NEURACAP
Sector OutlookPublished · 21 pages · Free to read

Medical Imaging Equipment Sector Outlook — September 2026

This report maps the Medical Imaging Equipment sector across nine approved companies, showing how forward EV/EBITDA multiples, business segment and precedent transactions separate value. It is built for owners, operators and boards assessing positioning and capital allocation in imaging equipment and instrumentation.

For information only. Not an appraisal or a fairness opinion.

What moved since: Medical Imaging Equipment M&A update, 14–28 September 2026

Key figures

Sector median EV/EBITDA (CY2027E)
9.2x
5 of 9 rated companies
Radiation instrumentation multiple
13.5x
Mirion Technologies, forward EV/EBITDA
Discount-end multiple
7.9x
Adjacent-imaging group, low end
Share in broad adjacent imaging
89%
8 of 9 approved companies

Read the report

NeuraCap

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL IMAGING EQUIPMENT

Medical Imaging Equipment: Where the Premium Sits, Size Is Not the Whole Story

The report shows how business mix, earnings durability and strategic fit separate value across imaging companies.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice

1

1 / 21

Executive summary

Medical Imaging Equipment splits between broad equipment platforms and a distinct radiation-instrumentation segment, and the forward valuation range follows that split more than it follows scale. The rated universe tops out with focused positioning and durable forward earnings, while the transaction record shows buyers pursuing both scaled platforms and targeted capabilities. For owners, the data points toward strengthening service attach and earnings durability as the lever most associated with the higher end of the range.

Key findings

  • Radiation instrumentation trades well above broad imaging peers on forward EV/EBITDA
  • 89% of approved names sit in broad adjacent imaging, not radiation instrumentation
  • Margin alone does not explain which names earn the higher forward multiple
  • Deal activity spans platform-scale and focused-capability transactions alike

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL IMAGING EQUIPMENT

    Cover page introducing the Medical Imaging Equipment sector outlook as of September 2026.

    We open this outlook by framing where Medical Imaging Equipment value concentrates as of September 2026. The pages that follow show why positioning, not scale, explains the gap.

    Everything on this page

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL IMAGING EQUIPMENT Medical Imaging Equipment: Where the Premium Sits, Size Is Not the Whole Story The report shows how business mix, earnings durability and strategic fit separate value across imaging companies. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This page lists the report's five sections plus an appendix, in the order they will be presented.

    We've structured this report so the answer comes first: Section 01, the bottom line, tells the whole story on its own. From there we move through the landscape, valuation and situations, precedent transactions and strategic implications. If time is short, section one alone leaves you with the full conclusion.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Medical Imaging Divides into Broad Platforms and Focused Radiation Instrumentation 02 The Landscape Broad Imaging Exposure Holds the Names; Radiation Instrumentation Holds the Premium 03 Valuation & Situations The Top of the Range Sits with Focused Positioning and Durable Forward Earnings 04 Precedent Transactions Buyers Pursue Both Scaled Platforms and Targeted Imaging Capabilities 05 Strategic Implications Value Improves When the Equipment Sale Supports a Durable Earnings Story 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Medical Imaging Equipment Splits Between Broad Platforms and Radiation Instrumentation

    This page summarizes the sector's core finding: value splits between broad imaging platforms and a distinct radiation-instrumentation premium.

    Eight of the nine approved names — 89% of the set — sit in the broad adjacent-imaging group, spanning established platforms and newer point-of-care models. Mirion Technologies, the sole radiation-instrumentation name, trades at 13.5x forward EV/EBITDA, well above the 7.9x seen at the discount end of the adjacent group. Among the five rated names, margin alone does not sort valuation — some names sit above both the multiple and the margin line, others do not. Deal activity backs this up: transactions span platform-scale deals like Hologic at $18.3B and focused-capability deals like View Point Medical at $140M. So what: the premium tracks positioning and earnings durability, not size.

    Everything on this page

    01 · THE BOTTOM LINE Medical Imaging Equipment Splits Between Broad Platforms and Radiation Instrumentation The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (5 of 9 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Most Names Sit in the Broad Adjacent Group 8 of 9 approved names sit in adjacent imaging, navigation and spine systems, representing 89% of the set. This group spans established platforms and newer point-of-care models, so commercial maturity varies within it. 2 Radiation Instrumentation Sits at the Top of the Range Mirion Technologies, Inc. (MIR) is the single radiation instrumentation name and carries 13.5x forward EV / EBITDA. The discount end is 7.9x across two adjacent-group names, suggesting different expectations for earnings durability. 3 Margin Alone Does Not Sort the Names Among the 5 names with a forward EV / EBITDA estimate, two sit above both valuation and the 18% margin line. One sits above the valuation line with a lower margin, while another shows the reverse. 4 Transactions Span Platform and Capability Deals Among transactions with disclosed values, Hologic, Inc is shown at $18.3B and View Point Medical, Inc. at $140M. The buyer mix is consistent with different paths to installed-base access and capability expansion. 9.2x Sector median EV/EBITDA CY2027E consensus · 5 rated of 9 companies 13.5x Premium end EV/EBITDA vs 7.9x at the discount end top quartile (n=1) against bottom quartile (n=2) on EV/EBITDA — the spread the report explains 11 Transactions with disclosed terms 22 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    Section divider introducing the market map of broad imaging exposure versus radiation instrumentation.

    This section maps the approved universe, showing how broad imaging exposure holds most of the names while radiation instrumentation holds the premium. We'll walk through where each segment sits before turning to valuation.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Broad Imaging Exposure Holds the Names; Radiation Instrumentation Holds the Premium The approved names span established equipment platforms, enabling technologies and newer point-of-care models. 02 of 06 Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Broad Imaging Holds the Set, While Focused Radiation Exposure Stands Apart

    This page groups the nine approved companies by business segment and shows the median EV/EBITDA per group.

    We group the approved universe into business segments to see where the multiples concentrate. Broad imaging holds the bulk of the names, while the radiation-instrumentation segment stands apart on its own. This separation is the first sign that the sector label covers more than one commercial model. So what: segment, not sector, is the right lens for valuation comparisons here.

    Everything on this page

    02 · MARKET MAP Broad Imaging Holds the Set, While Focused Radiation Exposure Stands Apart 9 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 ADJACENT: SPINE IMPLANTS WITH ENABLING IMAGING AND NAVIGATION 8 cos median 8.6x GE HealthCare (GEHC) Koninklijke (PHG) Globus Medical (GMED) Butterfly Network (BFLY) Alphatec Holdings (ATEC) Varex Imaging (VREX) Hyperfine (HYPR) Nano-X Imaging (NNOX) This group contains 89% of approved names and spans equipment, navigation, enabling technology and point-of-care models. RADIATION DETECTION, DOSIMETRY AND NUCLEAR IMAGING INSTRUMENTATION 1 cos 13.5x · 1 rated Mirion (MIR) This focused group links imaging instrumentation with radiation safety and dosimetry requirements.

  6. 06
    02 · LANDSCAPE

    One Sector Label Covers Two Distinct Commercial Models

    This page describes what each segment does and why the distinction matters commercially.

    We use this page to explain what each segment actually does — from established imaging platforms to focused radiation instrumentation — and why that difference shows up in the numbers. One label, two commercial models, is the read we carry into valuation. So what: understanding the model behind each name is a precondition for reading its multiple correctly.

    Everything on this page

    02 · LANDSCAPE One Sector Label Covers Two Distinct Commercial Models Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Adjacent: spine implants with enabling imaging and navigation 8 89% 8.6x GE HealthCare Technologies Inc. (GEHC) · Koninklijke Philips N.V. (PHG) · +6 more Broad, varied equipment exposure. These approved names serve imaging, navigation and adjacent procedural workflows. Their value stories differ with installed base, service attach, recurring mix and commercial maturity. Radiation detection, dosimetry and nuclear imaging instrumentation 1 11% 13.5x n=1 Mirion Technologies, Inc. (MIR) Focused radiation instrumentation. This group serves specialised detection, dosimetry and nuclear imaging needs. Regulatory obligations and focused applications distinguish its commercial position from broader equipment platforms.

  7. 07
    SECTION 03

    03

    Section divider introducing the valuation analysis, where the range tops out with focused positioning.

    This section turns to valuation: the top of the range sits with focused positioning and durable forward earnings. A forward EV/EBITDA lens already prices in expected performance, which raises the bar for any name claiming a sustained premium.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Top of the Range Sits with Focused Positioning and Durable Forward Earnings A forward EV / EBITDA lens already credits forecast performance, raising the test for a sustained premium. 03 of 06 Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Focused Positioning Holds the Top While Broader Names Fill the Lower End

    This page ranks the five rated companies by EV/EBITDA (CY2027E) against the 9.2x sector median.

    We rank all five rated companies on EV/EBITDA (CY2027E), sorted from highest to lowest against the 9.2x sector median. Focused positioning holds the top of the range, while broader names fill the lower end. The tier zones here are cut at the rated set's own quartiles, so the grouping reflects this specific cohort. So what: scale alone does not explain where a name sits in this range.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Focused Positioning Holds the Top While Broader Names Fill the Lower End EV / EBITDA (CY2027E) · all 5 rated companies, sorted descending · sector median 9.2x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (5 of 9 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 13.5x CORE · median 10.1x DISCOUNT · median 7.9x Sector median 9.2x WHAT SEPARATES THE TWO ENDS The top is specialised. The premium end is 13.5x and contains the focused radiation instrumentation name. Its positioning differs from the broader adjacent businesses at the lower end. The lower end is broader. The discount end is 7.9x across two adjacent-group names. Their placement shows that equipment breadth and profitability do not translate into the same forward valuation. Forward pricing raises the bar. The ranked page shows 9 approved names, with 5 names with a forward EV / EBITDA estimate. Because the multiple already credits forecast earnings, premium positioning also requires confidence in durability.

  9. 09
    03 · VALUATION DRIVERS

    Higher Margins Sit with the Top of the Range, and Business Quality Shows up in the Forward Earnings

    This page compares median valuation across revenue-growth and margin cohorts among the rated names with estimates.

    We split the rated names into growth and margin cohorts to see whether either explains the valuation spread. The pattern is directional, not causal: higher margins tend to sit with the top of the range, echoing what we saw in the segment view. We treat this as an association, not a driver we can prove from this data alone. So what: business quality shows up in the forward multiple, but it does not stand alone as an explanation.

    Everything on this page

    03 · VALUATION DRIVERS Higher Margins Sit with the Top of the Range, and Business Quality Shows up in the Forward Earnings Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=0; slower n=0; higher-margin n=0; lower-margin n=0). Driver readings are NeuraCap views on the supplied data — association, not causation. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 Profitability Supports Positioning Without Sorting the Range Cleanly The valuation-and-margin map contains names on both sides of each dividing line. Margin therefore needs to be considered with growth, mix and the durability of the earnings base. Installed Base Creates the Foundation for Recurring Economics A large, active fleet can support service, parts and consumables pull-through. Fleet age, modality mix and replacement-cycle position shape the quality of that opportunity. Service Attach Turns Equipment Placements into Durable Relationships Renewal, uptime and first-time-fix performance influence the value of the field service organisation. The important distinction is the economics that follow the initial system placement. Software Upgrades Can Deepen Returns from Existing Hardware Paid software and AI attach can expand the revenue opportunity within an installed base. The commercial test is whether customers adopt upgrades through normal budget and tender cycles.

  10. 10
    03 · SITUATION MAP

    The Five Forward-Earnings Names Occupy Four Different Operating Positions

    This page places the five forward-earnings names into four groups cut on valuation versus the 9.2x median and margin versus the 18% median.

    We cut the five rated names on two axes — EV/EBITDA against the 9.2x sector median, and EBITDA margin against the 18% covered median — to see where each one sits. The result is four distinct operating positions, not a single spectrum. These are observations on the data, not recommendations. So what: the same universe holds more than one credible strategic story, depending on where a name lands.

    Everything on this page

    03 · SITUATION MAP The Five Forward-Earnings Names Occupy Four Different Operating Positions Cut on EV / EBITDA vs the sector median (9.2x) (rows) and EBITDA margin vs the covered median (18%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium with Margin Support Above-median multiple · above-median EBITDA margin 2 names GE HealthCare Technologies Inc. (GEHC) · Mirion Technologies, Inc. (MIR) GE HealthCare Technologies Inc. (GEHC) and Mirion Technologies, Inc. (MIR) sit above both dividing lines. Their positions combine higher forward valuation with above-line profitability. Premium Before Margin Conversion Above-median multiple · below-median EBITDA margin 1 names Alphatec Holdings, Inc. (ATEC) Alphatec Holdings, Inc. (ATEC) sits above the valuation line and below the margin line. Its position places emphasis on translating growth and product momentum into sustained profitability. Margin Ahead of Valuation Below-median multiple · above-median EBITDA margin 1 names Globus Medical, Inc. (GMED) Globus Medical, Inc. (GMED) sits below the valuation line and above the margin line. Its position indicates that profitability alone is not associated with premium placement in this set. Both Measures Below Line Below-median multiple · below-median EBITDA margin 1 names Koninklijke Philips N.V. (PHG) Koninklijke Philips N.V. (PHG) sits below both dividing lines. Its position places greater weight on earnings improvement, mix and confidence in durability.

  11. 11
    03 · THE AGENDA

    Revenue Mix, Pricing and Build-Versus-Buy Are the Choices the Peer Valuations Point Toward

    This page frames the strategic questions — revenue mix, pricing and build-versus-buy — that the valuation spread raises for owners and acquirers.

    We turn the valuation spread into a set of questions: how revenue mix, pricing and build-versus-buy choices shape where a name sits in this range. These are framed as observations, not recommendations, grounded in the cohort data from the prior pages. So what: the peer set points to the decisions worth resolving next, even before a transaction is on the table.

    Everything on this page

    03 · THE AGENDA Revenue Mix, Pricing and Build-Versus-Buy Are the Choices the Peer Valuations Point Toward NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Deepen the Installed-Base Economics Service attach, renewal and parts and consumables pull-through can strengthen the earnings quality behind equipment placements. What changes the answer: The route gains weight when fleet utilisation is healthy but recurring participation remains underdeveloped. Expand Paid Upgrades on Existing Systems Software and AI attach can add value to the installed base without relying solely on new equipment placements. What changes the answer: The route gains weight when customers show adoption through existing procurement and budget channels. Improve Field Service Productivity Uptime, first-time-fix performance and field service cost can improve the economics of the service book. What changes the answer: The route gains weight when service demand is durable but delivery cost constrains profitability. Choose Build Versus Buy by Capability Gap Detector, tube, navigation and software gaps can be addressed internally or through a focused transaction. What changes the answer: The answer changes with technical differentiation, regulatory timing and access to the target customer channel.

  12. 12
    SECTION 04

    04

    Section divider introducing the precedent transaction record.

    This section reviews the transaction record, where buyers pursue both scaled platforms and targeted imaging capabilities. The deals span sponsor-backed platforms, imaging components and focused medical-device capabilities.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Buyers Pursue Both Scaled Platforms and Targeted Imaging Capabilities The transaction record spans sponsor-backed platforms, imaging components and focused medical-device capabilities. 04 of 06 Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    The Transaction Record Supports More than One Route to Strategic Relevance

    This page walks through three of eleven disclosed-terms transactions as case studies, including Hologic at $18.3B and View Point Medical at $140M.

    We walk through three of the eleven transactions with disclosed terms as case studies, spanning from Hologic at $18.3B down to View Point Medical at $140M. The multiples here are LTM at announcement, so they sit on a different basis than the CY2027E public multiples and we don't draw a spread between them. The buyer mix across these deals supports more than one route to strategic relevance — platform scale and focused capability both show up. So what: an owner's path to value is not limited to one size or one model.

    Everything on this page

    04 · DEAL CASE STUDIES The Transaction Record Supports More than One Route to Strategic Relevance 3 of 11 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 32 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 11 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Oct-2025 $18.3B Blackstone Inc.; TPG Capital Blackstone Inc.; TPG Capital acquired Hologic, Inc as a scaled healthcare platform. EV / LTM revenue 4.3x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The sponsor buyer group suggests an underwriting case centred on durable operating earnings and platform breadth. In imaging, installed-base and service economics can support that assessment. HOW THE TARGET WAS VALUED The disclosed value was $18.3B and the revenue multiple was 4.3x. That provides a scaled-platform benchmark within the transaction record. Aug-2026 $1.1B Teledyne Technologies Inc Teledyne Technologies Inc acquires Varex Imaging Corporation EV / LTM revenue 1.2x EV / LTM EBITDA 9.3x WHY THE DEAL HAPPENED The pairing suggests interest in imaging component capability, technical depth and customer access. It also fits the pattern of subsystem suppliers consolidating specialised capability. HOW THE TARGET WAS VALUED The disclosed value was $1.1B, with 1.2x EV / Revenue and 9.3x EV / EBITDA. The earnings multiple sits between the 8.0x and 11.3x transaction benchmarks in the record. Apr-2026 $140M Merit Medical Systems, Inc. Merit Medical Systems, Inc. agreed to acquire View Point Medical, Inc. as a focused addition to its… EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The pairing suggests that a broader medical-device owner saw strategic fit in View Point Medical, Inc. The transaction is consistent with buyers adding focused capabilities to existing commercial platforms. HOW THE TARGET WAS VALUED The disclosed value was $140M. That headline value is the usable benchmark for this focused capability transaction.

  14. 14
    SECTION 05

    05

    Section divider introducing strategic implications for owners on building durable earnings.

    This section turns to what owners can do: value improves when the equipment sale supports a durable earnings story. Service attach, recurring mix and focused capability all shape how a position can be strengthened.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Value Improves When the Equipment Sale Supports a Durable Earnings Story Service attach, recurring mix and focused capability shape how owners can strengthen positioning. 05 of 06 Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    For Owners, More Durable Forward Earnings Are Associated with the Higher Multiples

    This page sets out the strategic questions for owners, given that more durable forward earnings associate with higher multiples.

    We lay out the questions this data puts on the table for owners over the next twelve months. More durable forward earnings are associated with the higher multiples we've seen across this universe. These are directional views grounded in the analysis in this report, not recommendations. So what: strengthening earnings durability is the lever most consistent with the premium end of this range.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS For Owners, More Durable Forward Earnings Are Associated with the Higher Multiples NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Build Beyond the Equipment Placement A stronger position combines hardware demand with service attach, renewal and parts and consumables pull-through. The objective is a more durable earnings base across the replacement cycle. FOR OPERATORS Turn the Installed Base into Operating Evidence Focus on uptime, first-time-fix performance, upgrade adoption and field service cost. These operating levers shape the quality of recurring economics. FOR BOARDS Allocate Capital Around Capability and Channel Gaps Compare internal investment with focused acquisitions across components, software and customer access. Regulatory timing and commercial reach should shape the choice.

  16. 16
    SECTION 06

    06

    Section divider introducing the full comparables set, precedent transaction detail and methodology.

    This closing section carries the full universe, the methodology and the sources behind every figure in the body. Use it to trace any number back to where it came from.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    This appendix page lists all nine companies on EV/EBITDA (CY2027E), with five rated and four not rated, grouped by valuation tier.

    This appendix carries every comparable behind the report: five rated companies against the 9.2x sector median, plus four names without an eligible multiple. Teal marks a multiple above the median, amber marks below. Tickers link back to the underlying source for anyone who wants to verify a figure directly. So what: this is the full record behind the valuation view, not a curated subset.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (9.2x); amber marks below · 5 rated companies; 4 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 5 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥11.1x · median 13.5x · 1 companies Mirion Technologies, Inc. MIR Radiation detection, dosimetry and nuclear imaging… $4.5B 13.5x 7% 25% 34 CORE — 8.1x–11.1x · median 10.1x · 2 companies Alphatec Holdings, Inc. ATEC Adjacent: spine implants with enabling imaging and… $2.0B 11.1x 15% 16% 33 GE HealthCare Technologies Inc. GEHC Adjacent: spine implants with enabling imaging and… $38.9B 9.2x 5% 18% 23 DISCOUNT — <8.1x · median 7.9x · 2 companies Globus Medical, Inc. GMED Adjacent: spine implants with enabling imaging and… $9.6B 8.1x 6% 34% 41 Koninklijke Philips N.V. PHG Adjacent: spine implants with enabling imaging and… $30.6B 7.7x 4% 18% 23

  18. 18
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix page lists the eleven precedent transactions with disclosed terms, newest first, out of 22 recorded.

    We list all eleven transactions with disclosed terms here, newest first, out of the 22 recorded in this tier. Multiples are LTM at announcement, and deal values link to the underlying filing. So what: this is the primary evidence base behind the deal commentary earlier in the report.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 11 transactions with disclosed terms in this tier (22 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 32 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 11 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Aug-2026 Teledyne Technologies Inc → Varex Imaging Corporation $1.1B 1.2x 9.3x Teledyne Technologies Inc and Varex Imaging Corporation pair diversified technology ownership with imaging capability. The transaction suggests strategic interest in imaging components and customer access. Apr-2026 CJ CheilJedang Corp. → EDAP TMS SA n/a n/a 8.0x CJ CheilJedang Corp. agreed to acquire EDAP TMS SA. The pairing shows that buyer interest can extend beyond established imaging and medtech owners. Apr-2026 Merit Medical Systems, Inc. → View Point Medical, Inc. $140M n/a n/a Merit Medical Systems, Inc. agreed to acquire View Point Medical, Inc. The transaction places a focused medical capability within a broader medical-device owner. Oct-2025 Blackstone Inc.; TPG Capital → Hologic, Inc $18.3B 4.3x n/a Blackstone Inc.; TPG Capital acquired Hologic, Inc. The transaction suggests confidence in the earnings and operating profile of an established healthcare platform. Nov-2020 n/a → Butterfly Network, Inc. $1.9B 46.3x n/a The Butterfly Network, Inc. transaction sits within the record for newer imaging models. Such businesses are commonly assessed through installed-base development and the path toward recurring economics. Apr-2020 n/a → Substantially All Assets of CEO Imaging Systems, Inc. n/a 1.3x n/a Substantially All Assets of CEO Imaging Systems, Inc. entered the transaction record through an asset acquisition. This structure can isolate a specific operating capability from a broader organisation. Apr-2018 Altaris Capital Partners, LLC → Analogic Corporation n/a n/a 11.3x Altaris Capital Partners, LLC agreed to acquire Analogic Corporation. The pairing suggests a financial underwriting case around an established imaging equipment business. Dec-2014 Royal Philips NV → Volcano Corp. n/a 0.7x n/a Royal Philips NV acquired Volcano Corp. The pairing suggests a route to broaden imaging capability within an established healthcare platform. Dec-2013 Covidien plc → Given Imaging Ltd. n/a 5.2x n/a Covidien plc agreed to acquire Given Imaging Ltd. The transaction suggests strategic interest in adding focused imaging capability to a broader medical platform.

  19. 19
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix page continues the disclosed-terms transaction list, newest first.

    This page continues the same disclosed-terms list from the prior page, completing the eleven transactions out of 22 recorded. The same LTM-at-announcement basis applies throughout. So what: together, both pages give the complete disclosed-terms record behind the deal analysis.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 11 transactions with disclosed terms in this tier (22 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 32 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 11 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jan-2013 GSI Group Inc. → NDS Surgical Imaging n/a 0.7x n/a Value shown as recorded in the filing; deal value unit unresolved. n/a Undisclosed buyer → Bruker Corporation n/a 2.6x 15.3x Value shown as recorded in the filing; divestiture roles reassigned.

  20. 20
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This page documents the sources, assumptions and data-quality treatment behind the report.

    We use this page to show how the report was built: the valuation basis, what was excluded and why, and where each disclosure lives. Every figure in the report links back to its source, or the appendix names the basis on which it was read. So what: a client can trace any number in this deck back to its origin.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice 20 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (5 of 9 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Medical Imaging Equipment and it clears the coverage gate with 5 of 9 companies (56%). EV / Revenue, P / E are carried as a cross-check. The set earns: 5 of the 6 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 24 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 403 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (402) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  21. 21

    The Premium Sits with Distinct Positioning and Credible Forward Earnings.

    Closing page restating that the premium sits with distinct positioning and credible forward earnings.

    The premium in this sector sits with distinct positioning and credible forward earnings, not with size alone. The companion tables carry the full universe and source index for anyone who wants to go deeper.

    Everything on this page

    The Premium Sits with Distinct Positioning and Credible Forward Earnings. NeuraCap AI — Medical Imaging Equipment Coverage September 2026 · Prepared by NeuraCap AI · Confidential Medical Imaging Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21

Sources and methodology

This report covers Medical Imaging Equipment (Health Care › Health Care Equipment and Services › Medical Imaging Equipment) with market data and consensus estimates as of September 28, 2026. The company universe is the 9 listed companies whose core business is Medical Imaging Equipment according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Alphatec Holdings, Inc. (ATEC), Butterfly Network, Inc. (BFLY), GE HealthCare Technologies Inc. (GEHC), Globus Medical, Inc. (GMED), Hyperfine, Inc. (HYPR), Mirion Technologies, Inc. (MIR), Nano-X Imaging Ltd. (NNOX), Koninklijke Philips N.V. (PHG), Varex Imaging Corporation (VREX). The market map groups them by business vertical — Adjacent: spine implants with enabling imaging and navigation: 8 companies (GEHC, PHG, GMED, BFLY, ATEC, VREX, HYPR, NNOX); Radiation detection, dosimetry and nuclear imaging instrumentation: 1 company (MIR). 5 of the 9 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Medical Imaging Equipment (Health Care › Health Care Equipment and Services › Medical Imaging Equipment) with market data and consensus estimates as of September 28, 2026. The company universe is the 9 listed companies whose core business is Medical Imaging Equipment according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Alphatec Holdings, Inc. (ATEC), Butterfly Network, Inc. (BFLY), GE HealthCare Technologies Inc. (GEHC), Globus Medical, Inc. (GMED), Hyperfine, Inc. (HYPR), Mirion Technologies, Inc. (MIR), Nano-X Imaging Ltd. (NNOX), Koninklijke Philips N.V. (PHG), Varex Imaging Corporation (VREX). The market map groups them by business vertical — Adjacent: spine implants with enabling imaging and navigation: 8 companies (GEHC, PHG, GMED, BFLY, ATEC, VREX, HYPR, NNOX); Radiation detection, dosimetry and nuclear imaging instrumentation: 1 company (MIR). 5 of the 9 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

24 records failed a validation gate and never feed a statistic in this report (21 excluded from aggregate; 3 quarantined). Each exclusion, with its reason: ATEC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BFLY — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BFLY — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BFLY — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BFLY — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BFLY — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BFLY — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HYPR — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · HYPR — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · HYPR — Implied EBITDA margin -163.1% outside the plausible band [-100%, 80%] (effect: quarantined) · HYPR — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HYPR — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HYPR — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HYPR — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NNOX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · NNOX — Implied EBITDA margin -376.3% outside the plausible band [-100%, 80%] (effect: quarantined) · NNOX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · NNOX — Implied EBITDA margin -171.0% outside the plausible band [-100%, 80%] (effect: quarantined) · NNOX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · NNOX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NNOX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NNOX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NNOX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · VREX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (5 of 9 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Medical Imaging Equipment and it clears the coverage gate with 5 of 9 companies (56%). EV / Revenue, P / E are carried as a cross-check. The set earns: 5 of the 6 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 5 of 9 companies; EV / rEVenue: 9 of 9 companies; P/E: 5 of 9 companies. 1 company shows a non-meaningful EV / EBITDA denominator and is excluded from that statistic. 3 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥11.1x, Core 8.1x–11.1x, Discount <8.1x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 9.2x = median(ev_ebitda CY2027E) (5 rated companies) · 13.5x = median(ev_ebitda CY2027E) within Premium tier (n=1) · 10.1x = median(ev_ebitda CY2027E) within Core tier (n=2) · 7.9x = median(ev_ebitda CY2027E) within Discount tier (n=2) · 31% = median Rule of 40 score (revenue growth + EBITDA margin) (n=5)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Medical Imaging Equipment recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 22 transactions were recorded for this industry; 11 are shown. 11 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 13 × deal value unit unresolved; 14 × no evidence record; 3 × duplicate precedent id; 2 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 407 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Medical Imaging Equipment?

Company valuation reports run the same method against a single business — public or private.